Core products: Four pathways to innovation
One rtad platform enables multiple drug delivery routes and formulation strategies
Ultra-Concentrated >500 mg/mL mAbs
Subcutaneous injections of monoclonal antibodies
PATIENT BENEFITS
- Reduces administration time by hours
- Enables at-home self-administration
- Saves $150-200K ann. per patient
PHARMA BENEFITS
- Ultra-conc. >500 mg/mL mAbs
- Broader molecule landscape
- Franchise extension vs. biosimilars
Cold Chain-Free Biologics
Room Temperature Stability
PATIENT BENEFITS
- Global access & distribution
- Emerging market deployment
- Simplified storage
DEFENSE/GOV BENEFITS
- Field deployment capability
- Strategic stockpile ready
- Logistics elimination
Inhaled Biologics and Vaccines
Administered with Dry Powder Inhaler
PATIENT BENEFITS
- Eliminates cold chain requirements
- Convenient pulmonary delivery
- Global accessibility
PHARMA BENEFITS
- 5-10x production capacity gain
- Reduced FDA risk & timeline
- Broader molecule landscape
Intranasal Biologics and Vaccines
Administered with Nasal Spray & Powder Device
PATIENT BENEFITS
- Non-invasive administration
- Rapid absorption
- Room-temperature storage
PHARMA BENEFITS
- Non-invasive administration
- Rapid absorption
- Room-temperature storage
Why RTAD Changes the Equation
Capabilities that Conventional Biopharmaceutical Technologies Cannot Unlock
Enabling Biologic Formulations
Biologics that fail traditional drying-based formulation succeed with RTAD, achieving 10–100× less dehydration-induced damage to biologics.
Manufacturing De-Risk
Retrofit existing cGMP spray dryers instead of investing over $50M in greenfield facilities. RTAD offers a 12–18 month proven scale-up with digital twin validation.
Operational Capability
Room-temperature stability enables field deployment, creation of strategic stockpiles, and surge manufacturing for defense readiness.
Franchise Protection
Formulation IP blocks biosimilars for 5–7 years. Extend aging franchises against $120B patent cliffs through 2030.
Capacity Gains
Achieve 5–10× manufacturing capacity from existing infrastructure. Digital twin CFD predictive modeling helps to de-risk the scale-up process.
Speed to Clinic
RTAD provides a proven 100× feedstock scale-up within 12–18 months, compared to over 24 months for alternative methods. The consistent process is aligned with FDA-ready CMC standards.